Compound: Acalabrutinib
SMILES: O=C(N1[C@H](c2nc(-c3ccc(C(=O)Nc4ncccc4)cc3)c5n2ccnc5N)CCC1)C#CC
InChIKey: WDENQIQQYWYTPO-IBGZPJMESA-N
Synonyms: Acalabrutinib, 1420477-60-6, ACP-196, acalabrutinibum, I42748ELQW, 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide, Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-, CHEBI:167707, DTXSID401026209, 4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide, 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide, Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinylbenzamide, 4-(8-amino-3-((2S)-1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, 4-(8-amino-3-((2S)-1-but-2-ynoylpyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-pyridin-2-ylbenzamide, RefChem:57414, L01XE51, DTXCID401510462, Bruton Tyrosine Kinase Inhibitor ACP-196, 814-272-0, Calquence, Acalabrutinib (ACP-196), Acalabrutinib [INN], MFCD29472294, Acalabrutinib(ACP196), (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, Calquence (TN), 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide, Acalabrutinib [USAN:INN], UNII-I42748ELQW, C26H23N7O2, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; ACP 196, Acalabrutinib (Standard), ACP-196;Acalabrutinib, ACALABRUTINIB [MI], ACALABRUTINIB [JAN], ACALABRUTINIB [USAN], ACALABRUTINIB [WHO-DD], ACP196, GTPL8912, orb1303984, Acalabrutinib (JAN/USAN/INN), CHEMBL3707348, SCHEMBL14637368, SCHEMBL29376537, ACP 196, EX-A881, WDENQIQQYWYTPO-IBGZPJMESA-N, BDBM737806, GLXC-90498, ACALABRUTINIB [ORANGE BOOK], (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, BDBM50175583, EBC-17121, HY-17600R, NSC791164, NSC800976, s8116, AKOS030526094, CCG-269407, CS-5356, DB11703, DS-3326, NSC-791164, NSC-800976, US12291534, Compound Acalabrutinib, NCGC00479074-01, BP-43623, FA138815, HY-17600, SY099670, Example 6 [US20140155385 A1], NS00073620, D10893, EN300-7369651, BRD-K64034691-001-01-9, Q23668732, Z2238902271, 4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide
Theoretical properties:
molecular_formula: C26H23N7O2
molecular_weight: 465.5 g/mol
exact_mass: 465.19132300 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 4
heavy_atom_count: 35
topological_polar_surface_area: 119 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Freely soluble in water at pH values below 3 but is practically insoluble in water at pH values above 6
Descriptions:
{"pubchem": "Acalabrutinib is a member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It has a role as an antineoplastic agent, an apoptosis inducer and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a secondary carboxamide, a tertiary carboxamide, a member of benzamides, a member of pyridines, an aromatic amine, an imidazopyrazine, a pyrrolidinecarboxamide and a ynone.", "chebi": "A member of the class of imidazopyrazines that is imidazo[1,5-<em>a</em>]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2<i>S</i>)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.", "chembl": "ACALABRUTINIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Acalabrutinib, sold under the brand name Calquence, is an anti-cancer medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.  It may be used both in relapsed as well as in treatment-naive settings.\nCommon side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. It is a second generation Bruton's tyrosine kinase inhibitor. Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow. By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in chronic lymphocytic leukemia, thereby delaying progression of the cancer.\nAcalabrutinib was approved for medical use in the United States in 2017, and in the European Union in November 2020."}